Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) was the recipient of a large growth in short interest in July. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Get Seres Therapeutics alerts:Read Our Latest Research Report on Seres TherapeuticsInstitutional Trading of Seres TherapeuticsSeres Therapeutics Trading Down 3.1%Several institutional investors and hedge funds have recently modified their holdings of MCRB. Seres Therapeutics Company Profile(Get Free Report)Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Featured StoriesReceive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.